Figure 1 Effects of bevacizumab on vascular endothelial growth factor (VEGF; 20 ng/ml)‐mediated choroidal endothelial cell (CEC) permeability. In a CEC monolayer treated with 20 ng/ml VEGF, permeability is more than doubled compared with the basal flux in this fluorescent isothiocyanate‐dextran assay (p<0.01 at 3 h). Addition of 0.1 mg/ml bevacizumab inhibits VEGF‐induced permeability significantly (p<0.001). This effect can even be improved by increasing the dose of bevacizumab to 1 mg/ml (p<0.001). With 1 mg/ml of bevacizumab, the permeability of a VEGF‐treated CEC monolayer is reduced to the level of untreated monolayers. If just bevacizumab is added to non‐stimulated cells, there is no increase in permeability over time. *p<0.05; **p<0.01; ***p<0.001. SDs are shown.